Despite Pradaxa Risks, Pradaxa Approved for DVT
The manufacturer of the blood thinner Pradaxa, Boehringer Ingelheim Pharmaceuticals, recently announced that the U.S. Food and Drug Administration has approved the product for the treatment of pulmonary embolism (PE) and deep venous thrombosis (DVT) in those who have been treated with a parenteral anticoagulant for five to 10 days. Boehringer also stated that Pradaxa was approved to reduce the risk of recurrent PE and DVT in individuals who have been previously treated. This approval happened despite an increasing number of Pradaxa lawsuits throughout the U.S.
Pradaxa Approved for Pulmonary Embolism, DVT
An estimated 900,000 PE and DVT events occur each year in the U.S., approximately one-third of which result in death from PE. According to the director of Brigham and Women’s Hospital’s thrombosis research group, the two conditions combined is the third most common heart disease after stroke and myocardial infarction. Nearly one-third of patients with PE or DVT will suffer a recurrence within one decade.
Pradaxa was first approved in 2010 to prevent strokes in patients with atrial fibrillation and to prevent DVT in knee and hip replacement procedures. While Boehringer has stated that it is pleased that patients will now have an efficacious and new therapeutic option for PE and DVT, some experts in the medical community have raised concerns over the Pradaxa risks and complications that may result from use of the medication.
Since Pradaxa prevents a patient’s body from forming clots, one of the most common Pradaxa risks sustained by patients is internal bleeding. Plaintiffs filing lawsuits against Boehringer allege that the manufacturer knew of the Pradaxa risks, yet neglected to warn consumers or the healthcare community concerning the lack of a readily-available product to reverse severe internal bleeding.
Unlike other traditional blood thinners such as warfarin, there is no current antidote to reverse the anticlotting effects of Pradaxa. Whereas a patient suffering from internal bleeding while taking warfarin would benefit from a vitamin K injection, a patient experiencing the same condition due to Pradaxa has no option for a reversing agent and could potentially die from the medication, according to studies.
Have You Been Injured?
If you or someone you love has been injured while taking Pradaxa or you would like to learn more about Pradaxa risks and the lawsuits surrounding the product, contact the American Injury Attorney Group. We can provide a free consultation and help you determine whether you have a claim, and connect you with an affiliated attorney who can help you to pursue your claim. The time to file is limited, so contact us today to learn more about your legal rights and holding the manufacturer responsible for compensation for your injuries.